SARS-CoV-2 shedding dynamics across the respiratory tract, sex and disease severity for adult and pediatric COVID-19

Paul Z. Chen[1], Niklas Bobrovitz[2-4], Zahra Premji[5], Marion Koopmans[6], David N. Fisman[7], Frank X. Gu[1,8]*

[1]Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto, Canada

[2]Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

[3]Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

[4]O'Brien Institute of Public Health, University of Calgary, Calgary, Canada

[5]Libraries & Cultural Resources, University of Calgary, Calgary, Canada

[6]Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands

[7]Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

[8]Institute of Biomedical Engineering, University of Toronto, Toronto, Canada

Corresponding author: f.gu@utoronto.ca

Background: SARS-CoV-2 shedding dynamics influence the risk of transmission and clinical manifestations of COVID-19. Yet, the relationships between SARS-CoV-2 shedding dynamics in the upper (URT) and lower respiratory tract (LRT) and age, sex and COVID-19 severity remain unclear.

Methods: Using systematic review, we developed a dataset of case characteristics (age, sex and COVID-19 severity) and quantitative respiratory viral loads (rVLs). We then conducted stratified analyses to assess SARS-CoV-2 shedding across disease course, COVID-19 severity, the respiratory tract, sex and age groups (aged 0 to 17 years, 18 to 59 years, and 60 years or older).

Results: The systematic dataset included 1,266 adults and 136 children with COVID-19. In the URT, adults with severe COVID-19 had higher rVLs at 1 day from symptom onset (DFSO) than adults ($P = 0.005$) or children ($P = 0.017$) with nonsevere illness. Between 1-10 DFSO, severe adults had comparable rates of SARS-CoV-2 clearance from the URT as nonsevere adults ($P = 0.479$) and nonsevere children ($P = 0.863$). In the LRT, severe adults showed higher rVLs post-symptom onset than nonsevere adults ($P = 0.006$). In the analyzed period (4-10 DFSO), severely affected adults had no significant trend in SARS-CoV-2 clearance from LRT ($P = 0.105$), whereas nonsevere adults showed a clear trend ($P < 0.001$). After stratifying for disease severity, sex and age (including child vs. adult) were not predictive of the duration of respiratory shedding. The estimated accuracy for using URT shedding as a prognostic indicator for COVID-19 severity was up to 65%, whereas it was up to 81% for LRT shedding.

Conclusions: High, persistent LRT shedding of SARS-CoV-2 characterized severe COVID-19 in adults. After symptom onset, severe cases tended to have slightly higher URT shedding than their nonsevere counterparts. Disease severity, rather than age or sex, predicted SARS-CoV-2 kinetics. LRT specimens more accurately prognosticate COVID-19 severity than do URT specimens.

Funding: Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant, NSERC Senior Industrial Research Chair and the Toronto COVID-19 Action Fund.

50 **INTRODUCTION**

51 As of 13 May 2021, the coronavirus disease 2019 (COVID-19) pandemic has caused more than
52 160.5 million infections and 3.3 million deaths globally (Dong, Du, & Gardner, 2020). The
53 clinical spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2
54 (SARS-CoV-2), is wide, ranging from asymptomatic infection to fatal disease. Risk factors for
55 severe illness and death include age, sex, smoking and comorbidities, such as obesity,
56 hypertension, diabetes and cardiovascular disease (Onder, Rezza, & Brusaferro, 2020; Tartof et
57 al., 2020; Zhou et al., 2020). Cases that deteriorate into severe disease do so, on median, 10 days
58 from symptom onset (DFSO) (Berlin, Gulick, & Martinez, 2020; Zhou et al., 2020). Emerging
59 evidence indicates that age and sex differences in innate, cross-reactive and adaptive immunity
60 facilitate the higher risks observed in older and male cases (Ng et al., 2020; Pierce et al., 2020;
61 Rydyznski et al., 2020; Takahashi et al., 2020). Robust immune responses putatively mediate
62 nonsevere illness, in part, by controlling the replication of SARS-CoV-2 (Lucas et al., 2021;
63 Lucas et al., 2020).

64 As a respiratory virus, the shedding dynamics of SARS-CoV-2 in the upper (URT) and
65 lower respiratory tract (LRT) provide insight into clinical and epidemiological factors. URT viral
66 load has been associated with transmission risk, duration of infectiousness, disease severity and
67 mortality (Fu et al., 2021; Magleby et al., 2020; Marks et al., 2021; Pujadas et al., 2020; van
68 Kampen et al., 2021; Westblade et al., 2020; Wolfel et al., 2020). Key questions, however,
69 remain. While chest computed tomography (CT) evidence of viral pneumonitis suggests
70 pulmonary replication in most symptomatic cases (Bernheim et al., 2020), the LRT kinetics of
71 SARS-CoV-2, especially as related to disease severity, remain unknown. The relationships
72 between age, sex and disease severity on shedding dynamics are unclear, particularly for

73 children. Moreover, the accuracy of viral load in predicting COVID-19 severity is poorly
74 understood, with conflicting results for shedding dynamics based on analyses of low sample
75 numbers (Argyropoulos et al., 2020; Lucas et al., 2020; Pujadas et al., 2020; Silva et al., 2021;
76 Walsh et al., 2020; Westblade et al., 2020).

77 For insight into these questions, we conducted a systematic review on SARS-CoV-2
78 quantitation from respiratory specimens and developed a large, diverse dataset of respiratory
79 viral loads (rVLs) and individual case characteristics. Stratified analyses then assessed SARS-
80 CoV-2 shedding dynamics across the respiratory tract, age, sex and COVID-19 severity.

81

82 **RESULTS**

83 **Overview of contributing studies**

84 The systematic search (***Figure 1—Source Data 1 to 5***) identified 5,802 deduplicated results.
85 After screening and full-text review, 26 studies met the inclusion criteria (Methods), and data
86 were collected for individually reported specimens of known type with known DFSO and for
87 COVID-19 cases with known age, sex or severity (***Figure 1***). From 1,402 COVID-19 cases, we
88 collected 1,915 quantitative specimen measurements (viral RNA concentration in a respiratory
89 specimen) of SARS-CoV-2 (***Table 1***) and used them to estimate respiratory viral loads (rVLs,
90 viral RNA concentration in the respiratory tract) (Methods, ***Figure 1—Figure Supplement 1***).
91 For pediatric cases, the search found only nonsevere infections and URT specimen
92 measurements. ***Appendix Tables 1 and 2*** summarize the characteristics of contributing studies,
93 of which 18 had low risk of bias according to the modified JBI critical appraisal checklist.

94

95 **URT shedding of SARS-CoV-2 for adult COVID-19**

96 To interpret the complex interplay between SARS-CoV-2 shedding dynamics and age, sex and
97 COVID-19 severity, we stratified our systematic dataset into age, sex and severity groups and
98 then conducted a series of regression analyses. For adult COVID-19, regression analysis showed
99 that the mean URT rVL at 1 DFSO was significantly greater (*P* for intercept = 0.005) for
100 severely infected cases (8.28 [95% CI: 7.71-8.84] $\log_{10}$ copies/ml) than nonsevere ones (7.45
101 [95% CI: 7.26-7.65] $\log_{10}$ copies/ml) (***Figure 2, A and D***). Meanwhile, these groups showed
102 comparable URT dynamics post-symptom onset (*P* for interaction = 0.479), as severe adult cases
103 tended to cleared SARS-CoV-2 from the URT at -0.31 (95% CI: -0.40 to -0.22) $\log_{10}$ copies/ml
104 day^{-1} while nonsevere ones did so at -0.28 (95% CI: -0.32 to -0.24) copies/ml day^{-1} (***Figure 2, A***
105 ***and E***). For severe cases, the estimated mean duration of URT shedding (down to 0 $\log_{10}$
106 copies/ml) was 27.5 (95% CI: 21.2-33.8) DFSO; it was 27.9 (95% CI: 24.4-31.3) DFSO for
107 nonsevere cases.
108 After stratifying adults for disease severity, our analyses showed no significant differences
109 in URT shedding levels or dynamics between sex or age groups (***Figure 2, D and E, Figure 2—***
110 ***Figure Supplement 1***). For severe disease, male and female cases had comparable mean rVLs at
111 1 DFSO (*P* for intercept = 0.326) and rate of viral clearance (*P* for interaction = 0.280).
112 Similarly, for nonsevere illness, male and female cases had no significant difference in mean
113 rVL at 1 DFSO (*P* for intercept = 0.085) or URT dynamics (*P* for interaction = 0.644). For
114 nonsevere illness, younger and older adults had no significant difference in URT shedding levels
115 at 1 DFSO (*P* for intercept = 0.294) or post-symptom-onset dynamics (*P* for interaction = 0.100).
116 For severe disease, the adult age groups showed similar mean rVLs at 1 DFSO (*P* for intercept =
117 0.915) and rates of viral clearance (*P* for interaction = 0.359).
118

119 **URT shedding of SARS-CoV-2 for pediatric COVID-19**

120 For pediatric COVID-19, regression estimated, in the URT, the mean rVL at 1 DFSO to be 7.32
121 (95% CI: 6.78-7.86) $\log_{10}$ copies/ml and SARS-CoV-2 clearance rate as -0.32 (95% CI: -0.42 to
122 -0.22) $\log_{10}$ copies/ml day^{-1} (***Figure 2, F and G***). Both estimates were comparable between the
123 sexes for children (***Figure 2—Figure Supplement 1***). The estimated mean duration of URT
124 shedding (down to 0 $\log_{10}$ copies/ml) was 22.6 (95% CI: 17.0-28.1) DFSO for children with
125 COVID-19.

126 Between pediatric cases, who had nonsevere illness in our dataset, and adults with nonsevere
127 illness, both URT shedding at 1 DFSO (*P* for intercept = 0.653) and URT dynamics (*P* for
128 interaction = 0.400) were similar (***Figure 2, B, F and G***). Conversely, URT shedding at 1 DFSO
129 was greater for severely affected adults when compared to children with nonsevere disease (*P* for
130 intercept = 0.017), but URT dynamics remained similar (*P* for interaction = 0.863) (***Figure 2, C,***
131 ***F and G***).

132

133 **LRT shedding of SARS-CoV-2 for adult COVID-19**

134 For adults, our analyses showed that high, persistent LRT shedding of SARS-CoV-2 was
135 associated with severe COVID-19 but not nonsevere illness (***Figure 3A***). At the initial day in our
136 analyzed period (4 DFSO), the mean rVL in the LRT of severe cases (8.42 [95% CI: 7.67-9.17]
137 $\log_{10}$ copies/ml) was significantly greater (*P* for intercept = 0.006) than that of nonsevere cases
138 (6.82 [95% CI: 5.95-7.69] $\log_{10}$ copies/ml) (***Figure 3D***). Between severities, the difference in
139 LRT clearance rates was marginally above the threshold for statistical significance (*P* for
140 interaction = 0.053). Nonetheless, severe cases had persistent LRT shedding, with no significant
141 trend in SARS-CoV-2 clearance up to 10 DFSO (-0.14 [95% CI: -0.32 to 0.030] $\log_{10}$ copies/ml

142 day^{-1}, P = 0.105), whereas nonsevere cases rapidly cleared the virus from the LRT (-0.41 [95%
143 CI: -0.64 to -0.19] $\log_{10}$ copies/ml day^{-1}, P < 0.001) (***Figure 3E***). For nonsevere cases, the
144 estimated mean duration of LRT shedding (down to 0 $\log_{10}$ copies/ml) was 20.4 (95% CI: 13.2-
145 27.7) DFSO.

146 For severe COVID-19, regression analysis showed, in the LRT, comparable mean rVLs at 4
147 DFSO between younger and older adults (P for intercept = 0.745) (***Figure 3D***). For severe cases,
148 both age groups also showed persistent LRT shedding in the analyzed period: younger adults (-
149 0.20 [95% CI: -0.32 to 0.042] $\log_{10}$ copies/ml day^{-1}, P = 0.105) and older adults (-0.13 [95% CI:
150 -0.39 to 0.13] $\log_{10}$ copies/ml day^{-1}, P = 0.316) both had no significant trend in SARS-CoV-2
151 clearance (***Figure 3E, Figure 3—Figure Supplement 1A***). Likewise, severely affected male
152 cases had no significant trend in LRT shedding (0.001 [95% CI: -0.16 to 0.19] $\log_{10}$ copies/ml
153 day^{-1}, P = 0.988) (***Figure 3—Figure Supplement 1B***). The female group included few samples,
154 and statistically analyses were not conducted (**Appendix Table 3**).

155 Interestingly, nonsevere cases showed similar SARS-CoV-2 shedding between the URT and
156 LRT (***Figure 3B***), whereas severe cases shed greater and longer in the LRT than the URT
157 (***Figure 3C***). At 4 DFSO, the URT rVL of nonsevere adults was 6.62 (95% CI: 6.50-6.74) $\log_{10}$
158 copies/ml, which was not different from the LRT rVL of nonsevere adults (P for intercept =
159 0.651). In contrast, for severe adults, the rVL at 4 DFSO was significantly lower in the URT
160 (7.34 [95% CI: 7.01-7.68] $\log_{10}$ copies/ml) than the LRT (P for intercept = 0.031) (***Figure 3D***).
161

162 **Heterogeneity in URT shedding of SARS-CoV-2**

163 While regression analyses compared mean shedding levels and dynamics, we fitted rVLs to
164 Weibull distributions to assess the heterogeneity in rVL. Both severe and nonsevere adult

165 COVID-19 showed comparably broad distributions of URT shedding throughout disease course
166 (***Figure 4A***). For severe disease, the standard deviation (SD) of rVL was 1.86, 2.34, 1.89 and
167 1.90 $\log_{10}$ copies/ml at 2, 4, 7 and 10 DFSO, respectively. For nonsevere illness, these SDs were
168 2.08, 1.90, 1.89 and 1.96 $\log_{10}$ copies/ml, respectively. Notably, our distribution analyses
169 indicated that the top 2-9% of adults with COVID-19 harbored 80% of the SARS-CoV-2 copies
170 in the URT on each DFSO (***Figure 4—Figure Supplement 1, A to D***).
171 Since cases with severe COVID-19 tend to deteriorate at 10 DFSO (Berlin et al., 2020; Zhou
172 et al., 2020), the early differences in shedding may predict disease severity. To assess the
173 prognostic utility of URT shedding, we used the rVL distributions of nonsevere and severe adult
174 cases and calculated the area under the curve (AUC) that is overlapped or separated (***Figure 4B***).
175 The greater the separation between these rVL distributions, the greater the ability to differentiate
176 severe COVID-19 from nonsevere illness, and this AUC analysis estimates the maximal
177 accuracy of prognostication (Methods). At each DFSO, these URT distributions were largely
178 overlapped. Moreover, the cumulative density distributions of rVL (***Figure 4C***) estimated poor
179 sensitivity and specificity for prognostication (***Figure 4—Figure Supplement 2***). Thus, our data
180 indicated that URT shedding inaccurately predicts COVID-19 severity (***Figure 4D***).
181
182 **Heterogeneity in LRT shedding of SARS-CoV-2**
183 In contrast, the distributions of severe and nonsevere LRT shedding bifurcated along disease
184 course (***Figure 4E***). At 6 DFSO, the estimate at the 80th case percentile (cp) of LRT rVL was
185 9.40 (95% CI: 8.67-10.20) $\log_{10}$ copies/ml for severe COVID-19, while it was 7.66 (95% CI:
186 6.65-8.83) $\log_{10}$ copies/ml for nonsevere illness. At 10 DFSO, the difference between 80th-cp
187 estimates expanded, as they were 8.63 (95% CI: 8.04-9.26) and 6.01 (95% CI: 4.65-7.78) $\log_{10}$

188 copies/ml for severe and nonsevere disease, respectively. Moreover, our data indicated that
189 nonsevere illness was associated with greater skewing in LRT shedding than severe disease in
190 the analyzed period (***Figure 4E***). For nonsevere COVID-19, the SD of rVL was 1.92, 2.01 and
191 2.09 $\log_{10}$ copies/ml at 6, 8 and 10 DFSO, respectively. For severe disease, it was lesser at 1.25,
192 1.37 and 1.61 $\log_{10}$ copies/ml for 6, 8 and 10 DFSO, respectively. On each DFSO, the top 2-12%
193 of cases harbored 80% of the LRT copies of SARS-CoV-2 for adults with nonsevere COVID-19,
194 whereas it was the top 10-20% of cases for adults with severe disease (***Figure 4—Figure***
195 ***Supplement 1, E to H***).
196 We also assessed the prognostic utility of LRT shedding. We calculated the area under the
197 curve (AUC) that is overlapped or separated, which showed greater separation between the LRT
198 distributions of severe and nonsevere cases (***Figure 4, F and G***). The estimated accuracy for
199 using LRT shedding as a prognostic indicator for COVID-19 severity was up to 81% (***Figure***
200 ***4H***). We used the cumulative distributions of LRT shedding (***Figure 4G***) to estimate the
201 specificity and sensitivity at different prognostic thresholds of LRT shedding. For example, at 5
202 DFSO, the estimated specificity was 93.3% and the estimated sensitivity was 64.4% at a
203 prognostic threshold of 9.10 $\log_{10}$ copies/ml (***Figure 4—Figure Supplement 3***). For 8 DFSO,
204 the estimated specificity and sensitivity was 73.1 and 88.8%, respectively, at a prognostic
205 threshold of 5.95 $\log_{10}$ copies/ml. These estimated specificities and sensitivities agreed with the
206 estimated accuracy for prognostication. Taken together, our data indicated that LRT shedding
207 more accurately predicts COVID-19 severity than does URT shedding.
208
209 **DISCUSSION**

210 Our study systematically developed a dataset of COVID-19 case characteristics and rVLs and
211 conducted stratified analyses on SARS-CoV-2 shedding post-symptom onset. In the URT, we
212 found that adults with severe COVID-19 showed higher rVLs shortly after symptom onset, but
213 similar SARS-CoV-2 clearance rates, when compared with their nonsevere counterparts. In the
214 LRT, we found that high, persistent shedding was associated with severe COVID-19, but not
215 nonsevere illness, in adults. Interestingly, in the analyzed periods, adults with severe disease
216 tended to have higher rVLs in the LRT than the URT.

217 After stratifying for disease severity, we found that sex and age had nonsignificant effects on
218 post-symptom-onset SARS-CoV-2 shedding levels and dynamics for each included analysis
219 (summarized in ***Appendix Table 4***). Thus, while sex and age influence the tendency to develop
220 severe COVID-19 (Onder et al., 2020; Tartof et al., 2020; Zhou et al., 2020), we find no such sex
221 dimorphism or age distinction in shedding among cases of similar severity. This includes
222 children, who had nonsevere illness in our study and show similar URT shedding post-symptom
223 onset as adults with nonsevere illness.

224 Notably, our analyses indicate that high, persistent LRT shedding of SARS-CoV-2
225 characterizes severe COVID-19 in adults. This suggests that the effective immune responses
226 associated with milder COVID-19, including innate, cross-reactive and coordinated adaptive
227 immunity (Lucas et al., 2020; Ng et al., 2020; Pierce et al., 2020; Rydyznski et al., 2020;
228 Takahashi et al., 2020), do not significantly inhibit early, or prolonged, SARS-CoV-2 replication
229 in the LRT of severely affected adults. Hence, uncontrolled LRT replication tends to continue, at
230 least, to 10 DFSO, coinciding with the timing of clinical deterioration (median, 10 DFSO)
231 (Berlin et al., 2020; Zhou et al., 2020). Furthermore, the bifurcated profiles of LRT shedding
232 concur with the observed severity-associated differences in lung pathology, in which severe

233 cases show hyperinflammation and progressive loss of epithelial-endothelial integrity (Magro et
234 al., 2020; Matheson & Lehner, 2020; Z. Xu et al., 2020).

235 Our results indicate that LRT shedding may be a prognostic indicator in SARS-CoV-2
236 infection, predicting disease severity before clinical deterioration. They reinforce that severe
237 COVID-19 is associated with higher rVLs than nonsevere illness and suggest that sex and age
238 may not significantly influence prognostic thresholds. Nonsevere and severe cases tend to clear
239 SARS-CoV-2 from the LRT at different rates. Thus, time course of disease (e.g., DFSO) should
240 be considered alongside rVL, rather than simply employing rVL at admission. Unlike URT
241 shedding (our study predominantly analyzed nasopharyngeal and oropharyngeal swabs for URT
242 specimens), LRT shedding bifurcates considerably between nonsevere and severe COVID-19,
243 and SARS-CoV-2 quantitation from the LRT should more accurately predict severity. While
244 URT specimens are typically used to diagnose COVID-19, LRT specimens (our study
245 predominantly analyzed sputum) may be collected, especially from high-risk patients, for
246 severity prognostication.

247 While our analyses did not account for virus infectivity, higher SARS-CoV-2 rVL is
248 associated with a higher likelihood of culture positivity, from adults (van Kampen et al., 2021;
249 Wolfel et al., 2020) as well as children (L'Huillier, Torriani, Pigny, Kaiser, & Eckerle, 2020),
250 and higher transmission risk (Marks et al., 2021). Hence, our results suggest that infectiousness
251 increases with COVID-19 severity, concurring with epidemiological analyses (Li et al., 2021;
252 Sayampanathan et al., 2021). They also suggest that adult and pediatric infections of similar
253 severity have comparable infectiousness, reflecting epidemiological findings on age-based
254 infectiousness (Laxminarayan et al., 2020; Li et al., 2021; K. Sun et al., 2021). Moreover, since
255 respiratory aerosols are typically produced from the LRT (Johnson et al., 2011), severe SARS-

256 CoV-2 infections may have increased, and extended, risk for aerosol transmission. As severe
257 cases tend to be hospitalized, this provides one possible explanation for the elevated risk of
258 COVID-19 among healthcare workers in inpatient settings (Nguyen et al., 2020); airborne
259 precautions, such as the use of N95 or air-purifying respirators, should be implemented around
260 patients with COVID-19.

261 Our study has limitations. First, while our study design systematically developed a large,
262 diverse dataset, there were few severe female cases with LRT specimens and no severe pediatric
263 cases included. Statistical comparisons involving these groups were not conducted, and
264 additional studies should permit these remaining comparisons. Second, our analyses did not
265 assess the influence of additional case characteristics, including comorbidities, and their
266 relationships with SARS-CoV-2 kinetics remain unclear. Third, the systematic dataset consisted
267 largely of hospitalized patients, and our results may not generalize to asymptomatic infections.

268 In summary, our findings provide insight into SARS-CoV-2 kinetics and describe
269 virological factors that mediate the clinical manifestations of COVID-19. They show that high,
270 persistent LRT shedding characterizes severe disease in adults, highlighting the potential
271 prognostic utility of SARS-CoV-2 quantitation from LRT specimens. Lastly, each study
272 identified by our systematic review collected specimens before October 2020. As widespread
273 transmission of the emerging variants of concerns likely occurred after this date (Davies et al.,
274 2021; Tegally et al., 2021), our study presents a quantitative resource to assess the effects of their
275 mutations on respiratory shedding levels and dynamics.

276 **METHODS**

277 **Data sources and searches**

278 Our systematic review identified studies reporting SARS-CoV-2 quantitation in respiratory
279 specimens taken during the estimated infectious period (-3 to 10 days from symptom onset
280 [DFSO]) (He et al., 2020; Wolfel et al., 2020). The systematic review protocol was based on our
281 previous study (Chen et al., 2021) and was prospectively registered on PROSPERO (registration
282 number, CRD42020204637). The systematic review was conducted according to Cochrane
283 methods guidance (Higgins et al., 2019). Other than the title of this study, we have followed
284 PRISMA reporting guidelines (Moher, Liberati, Tetzlaff, Altman, & Group, 2009).

285 Up to 20 November 2020, we searched, without the use of filters or language restrictions,
286 the following sources: MEDLINE (Ovid, 1946 to 20 Nov 2020), EMBASE (Ovid, 1974 to 20
287 Nov 2020), Cochrane Central Register of Controlled Trials (via Ovid, 1991 to 20 Nov 2020),
288 Web of Science Core Collection (up to 20 Nov 2020), and medRxiv and bioRxiv (both searched
289 through Google Scholar via the Publish or Perish program, up to 20 Nov 2020). We also
290 gathered studies by searching through the reference lists of review articles identified by the
291 database search, by searching through the reference lists of included articles, through expert
292 recommendation (by Epic J. Topol and Akiko Iwasaki on Twitter) and by hand-searching
293 through journals. A comprehensive search was developed by a librarian (Z.P.). The line-by-line
294 search strategies for all databases are included in ***Figure 1—Source Data 1 to 5***. The search
295 results were exported from each database and uploaded to the Covidence online system for
296 deduplication and screening.

297

298 **Study selection**

299 Studies that reported SARS-CoV-2 quantitation in individual URT (nasopharyngeal swab
300 [NPS], nasopharyngeal aspirate [NPA], oropharyngeal swab [OPS] or posterior oropharyngeal
301 saliva [POS]) or LRT (endotracheal aspirate [ETA] or sputum [Spu]) specimens taken during the
302 estimated infectious period (-3 to 10 DFSO) in humans were included (additional details in the
303 **Appendix**). As semiquantitative metrics (cycle threshold [Ct] values) cannot be compared on an
304 absolute scale between studies based on instrument and batch variation (Han, Byun, Cho, & Rim,
305 2021), studies reporting specimen measurements as Ct values, without quantitative calibration,
306 were excluded. Two authors (P.Z.C. and N.B.) independently screened titles and abstracts and
307 reviewed full texts. At the full-text stage, reference lists were reviewed for study inclusion.
308 Inconsistencies were resolved by discussion and consensus, and 26 studies met the inclusion
309 criteria (Bal et al., 2020; Benotmane et al., 2020; Biguenet et al., 2021; Fajnzylber et al., 2020;
310 Han et al., 2020; Hirotsu et al., 2020; Hurst et al., 2020; Iwasaki et al., 2020; L'Huillier et al.,
311 2020; Lavezzo et al., 2020; Pan, Zhang, Yang, Poon, & Wang, 2020; Peng et al., 2020; Shrestha
312 et al., 2020; J. Sun et al., 2020; To et al., 2020; van Kampen et al., 2021; Vetter et al., 2020;
313 Wolfel et al., 2020; Wyllie et al., 2020; Y. Xu et al., 2020; Yazdanpanah, French, & study, 2021;
314 Yilmaz et al., 2021; Yonker et al., 2020; Zhang et al., 2020; Zheng et al., 2020; Zou et al., 2020).
315 Additional details on study selection can be found in our previous protocol (Chen et al., 2021)
316

317 **Data extraction and risk-of-bias assessment**

318 Two authors (P.Z.C. and N.B.) independently collected data (specimen measurements taken
319 between -3 and 10 DFSO, specimen type, volume of transport media and case characteristics,
320 including age, sex and disease severity) from contributing studies and assessed risk of bias using
321 a modified version of the Joanna Briggs Institute (JBI) tools for case series, analytical cross-

322 sectional studies and prevalence studies (Moola et al., 2020; Munn et al., 2019; Munn, Moola,
323 Lisy, Riitano, & Tufanaru, 2015) (shown in the **Appendix**). Items were judged with responses to
324 data inquiries, if authors responded.

325 Data were collected for individually reported specimens of known type, with known DFSO,
326 and for COVID-19 cases with known age, sex or severity. Case characteristics were collected
327 directly from contributing studies when reported individually or obtained via data request from
328 the authors. Data from serially sampled asymptomatic cases were included, and the day of
329 laboratory diagnosis was referenced as 0 DFSO (Lavezzo et al., 2020; Wolfel et al., 2020). Based
330 on the modified JBI checklist, studies were considered to have low risk of bias if they met the
331 majority of items and included item 1 (representative sample). Discrepancies were resolved by
332 discussion and consensus. Studies at high or unclear risk of bias typically included samples that
333 were not representative of the target population; did not report the VTM volume used; had non-
334 consecutive inclusion for case series and cohort studies or did not use probability-based sampling
335 for cross-sectional studies; and did not report the response rate.

336

337 **Respiratory viral load**

338 To enable analyses based on rVL (viral RNA concentration in the respiratory tract) and to
339 account for interstudy variation in specimen measurements, the rVL for each collected sample
340 was estimated based on the specimen concentration (viral RNA concentration in the specimen)
341 and its dilution factor in VTM. Typically, swabbed specimens (NPS and OPS) report the viral
342 RNA concentration in VTM. Based on the VTM volume reported in the study along with the
343 expected uptake volume for swabs (0.128 ± 0.031 ml, mean ± SD) (Warnke, Warning, &
344 Podbielski, 2014), we calculated the dilution factor for each respiratory specimen and then

345 estimated the rVL. Similarly, liquid specimens (ETA, POS and Spu) are often diluted in VTM,
346 and the rVL was estimated based on the reported collection and VTM volumes. If the diluent
347 volume was not reported, then VTM volumes of 1 ml (NPS and OPS) or 2 ml (POS and ETA)
348 were assumed (Lavezzo et al., 2020; To et al., 2020). Unless dilution was reported, Spu
349 specimens were taken as undiluted (Wolfel et al., 2020). The non-reporting of VTM volume was
350 noted as an element increasing risk of bias in the modified JBI critical appraisal checklist. For
351 laboratory-confirmed COVID-19 cases, negative specimen measurements were taken at the
352 reported assay detection limit in the respective study.
353
354 **Case definitions**
355 As severity in the clinical manifestations of COVID-19 and case-fatality rates tend to
356 increase among children (aged 0-17 y), younger adults (aged 18-59 y) and older adults (aged 60
357 y or older) (Onder et al., 2020; Zheng et al., 2020), the data were delineated based on these three
358 age groups. Cases were also categorized by sex.
359 U.S. National Institutes of Health guidance was used to categorize disease severity as
360 nonsevere or severe (Health). The nonsevere group included those with asymptomatic infection
361 (individuals who test positive via a molecular test for SARS-CoV-2 and report no symptoms
362 consistent with COVID-19); mild illness (individuals who report any signs or symptoms of
363 COVID-19, including fever, cough, sore throat, malaise, headache, muscle pain, nausea,
364 vomiting, diarrhea, loss of taste and smell, but who do not have dyspnea or abnormal chest
365 imaging); and moderate illness (individuals with clinical or radiographic evidence of LRT
366 disease, fever >39.4°C or $SpO_2 \geq 94\%$ on room air) disease. The severe group included those
367 with severe illness (individuals who have $SpO_2 < 94\%$ on room air, $[PaO_2/FiO_2] < 300$ mmHg,

368 respiratory rate >30 breaths/min or lung infiltrates >50%) and critical illness (respiratory failure,
369 septic shock or multiple organ dysfunction).
370
371 **Regression analyses**
372 We used regression analysis to assess the respiratory shedding of SARS-CoV-2 and compare
373 age, sex or severity groups. In COVID-19 cases, rVL tends to diminish exponentially after 1
374 DFSO in the URT, whereas it tends to do so after 4 DFSO in the LRT (Bernheim et al., 2020;
375 Chen et al., 2021; Wolfel et al., 2020). Hence, rVLs (in units of $\log_{10}$ copies/ml) between 1-10
376 DFSO for the URT, or 4-10 DFSO for the LRT, were fitted using general linear regression with
377 interaction:
378 $$V = \alpha + \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_1 X_2, \quad (1)$$
379 where V represents the rVL, α represents the estimated mean rVL (at 1 DFSO for URT or 4
380 DFSO for LRT) for the reference group, X_1 represents DFSO for the reference group, X_2
381 represents the comparison group, β_1 represents the effect of DFSO on rVL for the reference
382 group, β_2 represents the effect of the comparison group on the intercept and β_3 represents the
383 interaction between DFSO and groups. Regression analyses were offset by DFSO such that mean
384 rVLs at 1 DFSO for URT, or 4 DFSO for LRT, were compared between groups by the effect on
385 the intercept (regression *t*-test for β_2). Shedding dynamics were compared between groups by
386 interaction (regression *t*-test for β_3). The statistical significance of viral clearance for each group
387 was analyzed using simple linear regression (regression *t*-test on the slope). Regression models
388 were extrapolated (to 0 $\log_{10}$ copies/ml, rather than an assay detection limit) to estimate the
389 duration of shedding. Each group in statistical analyses included all rVLs for which the relevant
390 characteristic (LRT or URT, age group, sex or disease severity) was ascertained at the individual

391 level. Groups with small sample sizes were not compared, as these analyses are more sensitive to
392 potential sampling error. Statistical analyses were performed using OriginPro 2019b (OriginLab)
393 and the General Linear regression app. *P* values below 0.05 were considered statistically
394 significant.
395
396 **Distribution analyses**
397 To assess heterogeneity in shedding, rVL data were fitted to Weibull distributions (Chen et
398 al., 2021). The Weibull quantile function and Weibull cumulative distribution function were used
399 to estimate the rVL at a case percentile and the percentage of cases at a given rVL, respectively.
400 Each distribution was fitted to groups that included all rVLs for which the relevant characteristic
401 (LRT or URT, age group, sex or disease severity) was ascertained at the individual level.
402 Distribution fitting was performed using Matlab R2019b (MathWorks) and the Distribution
403 Fitter app.
404
405 **Prognostication accuracy**
406 The fitted Weibull distributions were used to estimate the accuracy when using URT or LRT
407 rVLs of SARS-CoV-2 as a prognostic indicator for SARS-CoV-2 infection. The overlapped
408 AUC and separated AUC were calculated using the rVL distributions for severe and nonsevere
409 adult COVID-19. These calculations were performed on separate DFSO and, separately, for the
410 URT and LRT. The estimated maximal accuracy for prognostication at a given rVL threshold
411 was then estimated by $A = 50\% + (50\% * AUC_{separated})$, where $AUC_{separated}$ represents the
412 separated AUC for the nonsevere and severe distributions. The 95% CIs for prognostication
413 accuracy were estimated using the proportional 95% CIs in the respective Weibull cumulative

414 distributions. As the Weibull cumulative distributions estimate the percentage of cases at a given
415 rVL, they were also used to estimate the sensitivity and specificity at a given prognostic
416 threshold of rVL. By definition, the cases with rVL lower than the prognostic threshold are
417 predicted to have nonsevere COVID-19, whereas those with rVL above it are predicted to have
418 severe COVID-19. Hence, we used the cumulative distributions for nonsevere and severe adult
419 cases on a DFSO and calculated the proportion of cases that were true positive, false positive,
420 false negative and true negative rates across prognostic thresholds of rVL. Sensitivity and
421 specificity were calculated based on these values.

References

Argyropoulos, K. V., Serrano, A., Hu, J., Black, M., Feng, X., Shen, G., . . . Jour, G. (2020). Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms. *American Journal of Pathology, 190*(9), 1881-1887. doi:10.1016/j.ajpath.2020.07.001

Bal, A., Brengel-Pesce, K., Gaymard, A., Quéromès, G., Guibert, N., Frobert, E., . . . Trouillet-Assant, S. (2020). Clinical and microbiological assessments of COVID-19 in healthcare workers: a prospective longitudinal study. *medRxiv*. doi:10.1101/2020.11.04.20225862

Benotmane, I., Gautier-Vargas, G., Wendling, M. J., Perrin, P., Velay, A., Bassand, X., . . . Fafi-Kremer, S. (2020). In-depth virological assessment of kidney transplant recipients with COVID-19. *American Journal of Transplantation, 20*(11), 3162-3172. doi:10.1111/ajt.16251

Berlin, D. A., Gulick, R. M., & Martinez, F. J. (2020). Severe Covid-19. *New England Journal of Medicine, 383*(25), 2451-2460. doi:10.1056/NEJMcp2009575

Bernheim, A., Mei, X., Huang, M., Yang, Y., Fayad, Z. A., Zhang, N., . . . Chung, M. (2020). Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiology, 295*(3), 200463. doi:10.1148/radiol.2020200463

Biguenet, A., Bouiller, K., Marty-Quinternet, S., Brunel, A. S., Chirouze, C., & Lepiller, Q. (2021). SARS-CoV-2 respiratory viral loads and association with clinical and biological features. *Journal of Medical Virology, 93*(3), 1761-1765. doi:10.1002/jmv.26489

Chen, P. Z., Bobrovitz, N., Premji, Z., Koopmans, M., Fisman, D. N., & Gu, F. X. (2021). Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols. *Elife, 10*, e65774. doi:10.7554/eLife.65774

Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., . . . Edmunds, W. J. (2021). Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science, 372*(6538). doi:10.1126/science.abg3055

Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infectious Diseases, 20*(5), 533-534. doi:10.1016/S1473-3099(20)30120-1

Fajnzylber, J., Regan, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., . . . Massachusetts Consortium for Pathogen, R. (2020). SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun, 11*(1), 5493. doi:10.1038/s41467-020-19057-5

Fu, Y., Li, Y., Guo, E., He, L., Liu, J., Yang, B., . . . Chen, G. (2021). Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19 : A Retrospective Study. *Annals of Internal Medicine, 174*(4), 453-461. doi:10.7326/M20-3337

Han, M. S., Byun, J. H., Cho, Y., & Rim, J. H. (2021). RT-PCR for SARS-CoV-2: quantitative versus qualitative. *Lancet Infectious Diseases, 21*(2), 165. doi:10.1016/S1473-3099(20)30424-2

Han, M. S., Seong, M. W., Kim, N., Shin, S., Cho, S. I., Park, H., . . . Choi, E. H. (2020). Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul, South Korea. *Emerging Infectious Diseases, 26*(10), 2497-2499. doi:10.3201/eid2610.202449

He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., . . . Leung, G. M. (2020). Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine, 26*(5), 672-675. doi:10.1038/s41591-020-0869-5

Health, N. I. o. Clinical spectrum of SARS-CoV-2 infection. Accessed at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum on 1 February 2020.

Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2019). *Cochrane handbook for systematic reviews of interventionsCochrane book series* (2nd edition. ed.). doi:10.1002/9781119536604

Hirotsu, Y., Maejima, M., Shibusawa, M., Nagakubo, Y., Hosaka, K., Amemiya, K., . . . Omata, M. (2020). Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. *International Journal of Infectious Diseases, 99*, 397-402. doi:10.1016/j.ijid.2020.08.029

Hurst, J. H., Heston, S. M., Chambers, H. N., Cunningham, H. M., Price, M. J., Suarez, L., . . . Kelly, M. S. (2020). SARS-CoV-2 infections among children in the biospecimens from respiratory virus-exposed kids (BRAVE Kids) study. *Clinical Infectious Diseases*. doi:10.1093/cid/ciaa1693

Iwasaki, S., Fujisawa, S., Nakakubo, S., Kamada, K., Yamashita, Y., Fukumoto, T., . . . Teshima, T. (2020). Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. *Journal of Infection, 81*(2), e145-e147. doi:10.1016/j.jinf.2020.05.071

Johnson, G. R., Morawska, L., Ristovski, Z. D., Hargreaves, M., Mengersen, K., Chao, C. Y. H., . . . Corbett, S. (2011). Modality of human expired aerosol size distributions. *Journal of Aerosol Science, 42*(12), 839-851. doi:10.1016/j.jaerosci.2011.07.009

L'Huillier, A. G., Torriani, G., Pigny, F., Kaiser, L., & Eckerle, I. (2020). Culture-competent SARS-CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerging Infectious Diseases, 26*(10), 2494-2497. doi:10.3201/eid2610.202403

Lavezzo, E., Franchin, E., Ciavarella, C., Cuomo-Dannenburg, G., Barzon, L., Del Vecchio, C., . . . Imperial College, C.-R. T. (2020). Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature, 584*(7821), 425-429. doi:10.1038/s41586-020-2488-1

Laxminarayan, R., Wahl, B., Dudala, S. R., Gopal, K., Mohan, B. C., Neelima, S., . . . Lewnard, J. A. (2020). Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science, 370*(6517), 691-697. doi:10.1126/science.abd7672

Li, F., Li, Y. Y., Liu, M. J., Fang, L. Q., Dean, N. E., Wong, G. W. K., . . . Xu, S. Q. (2021). Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. *Lancet Infectious Diseases, 21*(5), 617-628. doi:10.1016/S1473-3099(20)30981-6

Lucas, C., Klein, J., Sundaram, M. E., Liu, F., Wong, P., Silva, J., . . . Iwasaki, A. (2021). Delayed production of neutralizing antibodies correlates with fatal COVID-19. *Nature Medicine*. doi:10.1038/s41591-021-01355-0

Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., . . . Iwasaki, A. (2020). Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature, 584*(7821), 463-469. doi:10.1038/s41586-020-2588-y

Magleby, R., Westblade, L. F., Trzebucki, A., Simon, M. S., Rajan, M., Park, J., . . . Satlin, M. J. (2020). Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. *Clinical Infectious Diseases*. doi:10.1093/cid/ciaa851

Magro, C., Mulvey, J. J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., . . . Laurence, J. (2020). Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Translational Research: The Journal of Laboratory and Clinical Medicine, 220*, 1-13. doi:10.1016/j.trsl.2020.04.007

Marks, M., Millat-Martinez, P., Ouchi, D., Roberts, C. H., Alemany, A., Corbacho-Monne, M., . . . Mitja, O. (2021). Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infectious Diseases, 21*(5), 629-636. doi:10.1016/S1473-3099(20)30985-3

Matheson, N. J., & Lehner, P. J. (2020). How does SARS-CoV-2 cause COVID-19? *Science, 369*(6503), 510-511. doi:10.1126/science.abc6156

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine, 6*(7), e1000097. doi:10.1371/journal.pmed.1000097

Moola, S., Munn, Z., Tufanaru, C., Aromataris, E., Sears, K., Sfetcu, R., . . . Mu, P. (2020). Chapter 7: systematic reviews of etiology and risk. In E. Aromataris & Z. Munn (Eds.), *Joanna Briggs Institute Reviewer's Manual. The Joanna Briggs Institute* (pp. 2019-2005): The Joanna Briggs Institute.

Munn, Z., Barker, T. H., Moola, S., Tufanaru, C., Stern, C., McArthur, A., . . . Aromataris, E. (2019). Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. *JBI Database System Rev Implement Rep*. doi:10.11124/JBISRIR-D-19-00099

Munn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015). Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc, 13*(3), 147-153. doi:10.1097/XEB.0000000000000054

Ng, K. W., Faulkner, N., Cornish, G. H., Rosa, A., Harvey, R., Hussain, S., . . . Kassiotis, G. (2020). Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science, 370*(6522), 1339-1343. doi:10.1126/science.abe1107

Nguyen, L. H., Drew, D. A., Graham, M. S., Joshi, A. D., Guo, C. G., Ma, W. J., . . . Epidemiology, C. P. (2020). Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health, 5*(9), E475-E483. doi:10.1016/S2468-2667(20)30164-X

Onder, G., Rezza, G., & Brusaferro, S. (2020). Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA, 323*(18), 1775-1776. doi:10.1001/jama.2020.4683

Pan, Y., Zhang, D., Yang, P., Poon, L. L. M., & Wang, Q. (2020). Viral load of SARS-CoV-2 in clinical samples. *Lancet Infectious Diseases, 20*(4), 411-412. doi:10.1016/S1473-3099(20)30113-4

Peng, L., Liu, J., Xu, W., Luo, Q., Chen, D., Lei, Z., . . . Gao, Z. (2020). SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. *Journal of Medical Virology, 92*(9), 1676-1680. doi:10.1002/jmv.25936

Pierce, C. A., Preston-Hurlburt, P., Dai, Y., Aschner, C. B., Cheshenko, N., Galen, B., . . . Herold, B. C. (2020). Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Science Translational Medicine, 12*(564). doi:10.1126/scitranslmed.abd5487

Pujadas, E., Chaudhry, F., McBride, R., Richter, F., Zhao, S., Wajnberg, A., . . . Cordon-Cardo, C. (2020). SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir Med, 8*(9), e70. doi:10.1016/S2213-2600(20)30354-4

Rydyznski, M. C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., . . . Crotty, S. (2020). Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell, 183*(4), 996-1012 e1019. doi:10.1016/j.cell.2020.09.038

Sayampanathan, A. A., Heng, C. S., Pin, P. H., Pang, J., Leong, T. Y., & Lee, V. J. (2021). Infectivity of asymptomatic versus symptomatic COVID-19. *Lancet, 397*(10269), 93-94. doi:10.1016/S0140-6736(20)32651-9

Shrestha, N. K., Marco Canosa, F., Nowacki, A. S., Procop, G. W., Vogel, S., Fraser, T. G., . . . Gordon, S. M. (2020). Distribution of transmission potential during nonsevere COVID-19 illness. *Clinical Infectious Diseases, 71*(11), 2927-2932. doi:10.1093/cid/ciaa886

Silva, J., Lucas, C., Sundaram, M., Israelow, B., Wong, P., Klein, J., . . . Iwasaki, A. (2021). Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. doi:10.1101/2021.01.04.21249236

Sun, J., Tang, X., Bai, R., Liang, C., Zeng, L., Lin, H., . . . Ke, C. (2020). The kinetics of viral load and antibodies to SARS-CoV-2. *Clinical Microbiology and Infection, 26*(12), 1690 e1691-1690 e1694. doi:10.1016/j.cmi.2020.08.043

Sun, K., Wang, W., Gao, L., Wang, Y., Luo, K., Ren, L., . . . Yu, H. (2021). Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. *Science, 371*(6526), eabe2424. doi:10.1126/science.abe2424

Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., . . . Iwasaki, A. (2020). Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature, 588*(7837), 315-320. doi:10.1038/s41586-020-2700-3

Tartof, S. Y., Qian, L., Hong, V., Wei, R., Nadjafi, R. F., Fischer, H., . . . Murali, S. B. (2020). Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. *Annals of Internal Medicine, 173*(10), 773-781. doi:10.7326/M20-3742

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., . . . de Oliveira, T. (2021). Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature, 592*(7854), 438-443. doi:10.1038/s41586-021-03402-9

To, K. K., Tsang, O. T., Leung, W. S., Tam, A. R., Wu, T. C., Lung, D. C., . . . Yuen, K. Y. (2020). Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infectious Diseases, 20*(5), 565-574. doi:10.1016/S1473-3099(20)30196-1

van Kampen, J. J. A., van de Vijver, D., Fraaij, P. L. A., Haagmans, B. L., Lamers, M. M., Okba, N., . . . van der Eijk, A. A. (2021). Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun, 12*(1), 267. doi:10.1038/s41467-020-20568-4

Vetter, P., Eberhardt, C. S., Meyer, B., Martinez Murillo, P. A., Torriani, G., Pigny, F., . . . Eckerle, I. (2020). Daily viral kinetics and innate and adaptive immune response assessment in COVID-19: a case series. *mSphere, 5*(6). doi:10.1128/mSphere.00827-20

Walsh, K. A., Jordan, K., Clyne, B., Rohde, D., Drummond, L., Byrne, P., . . . Harrington, P. (2020). SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *Journal of Infection, 81*(3), 357-371. doi:10.1016/j.jinf.2020.06.067

Warnke, P., Warning, L., & Podbielski, A. (2014). Some are more equal - a comparative study on swab uptake and release of bacterial suspensions. *PloS One, 9*(7), e102215. doi:10.1371/journal.pone.0102215

Westblade, L. F., Brar, G., Pinheiro, L. C., Paidoussis, D., Rajan, M., Martin, P., . . . Satlin, M. J. (2020). SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. *Cancer Cell, 38*(5), 661-671 e662. doi:10.1016/j.ccell.2020.09.007

583 Wolfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M. A., . . . Wendtner, C. (2020).
584 Virological assessment of hospitalized patients with COVID-2019. *Nature, 581*(7809), 465-469.
585 doi:10.1038/s41586-020-2196-x
586 Wyllie, A. L., Fournier, J., Casanovas-Massana, A., Campbell, M., Tokuyama, M., Vijayakumar, P., . . . Ko, A. I.
587 (2020). Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. *New England Journal of*
588 *Medicine, 383*(13), 1283-1286. doi:10.1056/NEJMc2016359
589 Xu, Y., Li, X., Zhu, B., Liang, H., Fang, C., Gong, Y., . . . Gong, S. (2020). Characteristics of pediatric SARS-CoV-
590 2 infection and potential evidence for persistent fecal viral shedding. *Nature Medicine, 26*(4), 502-505.
591 doi:10.1038/s41591-020-0817-4
592 Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., . . . Wang, F. S. (2020). Pathological findings of
593 COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med, 8*(4), 420-422.
594 doi:10.1016/S2213-2600(20)30076-X
595 Yazdanpanah, Y., French, C. c. i., & study, g. (2021). Impact on disease mortality of clinical, biological, and
596 virological characteristics at hospital admission and overtime in COVID-19 patients. *Journal of Medical*
597 *Virology, 93*(4), 2149-2159. doi:10.1002/jmv.26601
598 Yilmaz, A., Marklund, E., Andersson, M., Nilsson, S., Andersson, L. M., Lindh, M., & Gisslen, M. (2021). Upper
599 respiratory tract levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and duration of viral
600 RNA shedding do not differ between patients with mild and severe/critical Coronavirus Disease 2019.
601 *Journal of Infectious Diseases, 223*(1), 15-18. doi:10.1093/infdis/jiaa632
602 Yonker, L. M., Neilan, A. M., Bartsch, Y., Patel, A. B., Regan, J., Arya, P., . . . Fasano, A. (2020). Pediatric severe
603 acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune
604 responses. *Journal of Pediatrics, 227*, 45-52. doi:10.1016/j.jpeds.2020.08.037
605 Zhang, N., Gong, Y., Meng, F., Shi, Y., Wang, J., Mao, P., . . . Wang, F. (2020). Comparative study on virus
606 shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients. *Sci China Life Sci*.
607 doi:10.1007/s11427-020-1783-9
608 Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., . . . Liang, T. (2020). Viral load dynamics and disease severity
609 in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective
610 cohort study. *BMJ, 369*, m1443. doi:10.1136/bmj.m1443
611 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., . . . Cao, B. (2020). Clinical course and risk factors for mortality
612 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet, 395*(10229), 1054-
613 1062. doi:10.1016/S0140-6736(20)30566-3
614 Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., . . . Wu, J. (2020). SARS-CoV-2 viral load in upper
615 respiratory specimens of infected patients. *New England Journal of Medicine, 382*(12), 1177-1179.
616 doi:10.1056/NEJMc2001737
617
618

619 **Acknowledgement:** The authors thank S. Fafi-Kremer, PharmD, PhD (Strasbourg University
620 Hospital); Y. Hirotsu, PhD (Yamanashi Central Hospital); M.S. Kelly, MD, MPH (Duke
621 University); E. Lavezzo, PhD, and A. Crisanti, MD, PhD (University of Padova); J.Z. Li, MD,
622 MMSc (Brigham & Women's Hospital); Cédric Laouénan, MD, PhD, and Yazdan Yazdanpanah,
623 MD, PhD (Bichat-Claude Bernard University Hospital); N.K. Shrestha, MD (Cleveland Clinic);
624 T. Teshima, MD, PhD (Hokkaido University); S. Trouillet-Assant, PhD (Université Hospital of
625 Lyon); J.J.A. van Kampen, MD, PhD (Erasmus University Medical Center); A. Wyllie, PhD, N.

Grubaugh, PhD, and A. Ko, MD (Yale School of Public Health); and A. Yilmaz, MD, PhD (Sahlgrenska University Hospital) for responses to data inquiries.

Financial support: This study was supported by NSERC. P.Z.C. was supported by the NSERC Vanier Canada Graduate Scholarship (608544). D.N.F was supported by the Canadian Institutes of Health Research (Canadian COVID-19 Rapid Research Fund, OV4-170360). F.X.G. was supported by the NSERC Discovery Grant, NSERC Senior Industrial Research Chair program and Toronto COVID-19 Action Fund.

Data availability: The systematic dataset and model outputs from this study will be uploaded to Zenodo after peer review. The systematic review protocol was prospectively registered on PROSPERO (registration number, CRD42020204637).

638 **Table 1.** Characteristics of adult and pediatric COVID-19 cases in the systematic dataset

	Adult	**Pediatric**
Cases, *n*	1 266	136
URT specimens, *n*	1 513	192
LRT specimens, *n*	210	0
Mean age (SD), *y*	51.8 (18.0)	8.7 (5.3)
Male, *n (%)*	528 (44.0)	63 (52.5)
Disease severity, *n (%)*		
Asymptomatic	2 (0.2)	5 (3.7)
Mild	710 (57.5)	112 (83.6)
Moderate	178 (14.4)	17 (12.7)
Severe	167 (13.5)	0 (0.0)
Critical	178 (14.4)	0 (0.0)

639 Adult cases were those aged 18 y or older, while pediatric cases were those aged younger than 18

640 y. Upper respiratory tract = URT. Lower respiratory tract = LRT.



641

642 **Figure 1.** Study selection.



Figure 2. Comparison of SARS-CoV-2 shedding in the URT across disease severity, sex and age groups. (**A** to **C**)**.** Upper respiratory tract (URT) shedding for severe and nonsevere adult (aged 18 y or older) COVID-19 (A), for nonsevere pediatric (aged 0-17 y) and nonsevere adult COVID-19 (B) and for nonsevere pediatric and severe adult COVID-19 (C). Open circles represent rVL data and were offset from their DFSO for visualization. Lines and bands show regressions and their 95% CIs, respectively. (**D** and **E**) Comparisons of URT shedding levels at 1 day from symptom onset (DFSO) (D) and URT shedding dynamics (E) between severity, age

651 and sex groups for COVID-19. (**F** and **G**) Comparisons of URT shedding levels at 1 DFSO (F)
652 and URT shedding dynamics (G) between pediatric and adult groups for COVID-19. The black
653 line in (E) and (G) depicts 0, the threshold for no significant trend in SARS-CoV-2 clearance.
654 Regression analyses determined *P* values and compared shedding levels and dynamics between
655 the two groups in each row.



Figure 3. Comparison of SARS-CoV-2 shedding in the LRT across disease severity and age groups and the respiratory tract. (**A** to **C**)**.** Shedding in the lower respiratory tract (LRT) for severe and nonsevere adult (aged 18 y or older) COVID-19 (A), in the LRT and upper respiratory tract (URT) nonsevere adult COVID-19 (B) and in the LRT and URT severe adult COVID-19 (C). Open circles represent rVL data and were offset from their DFSO for visualization. Lines and bands show regressions and their 95% CIs, respectively. (**D** and **E**) Comparisons of shedding levels at 4 day from symptom onset (DFSO) (D) and URT shedding dynamics (E) between severity and age groups in the LRT and between the LRT and URT. The black line in (E) depicts 0, the threshold for no significant trend in SARS-CoV-2 clearance. Regression analyses determined *P* values and compared shedding levels and dynamics between the two groups in each row.



Fig. 4. Heterogeneity in, and severity prognostication from, SARS-CoV-2 shedding for adult COVID-19. (**A**) Estimated distributions at 2, 4, 7 and 10 days from symptom onset

671 (DFSO) of upper respiratory tract (URT) shedding for adults (aged 18 y or older) with nonsevere
672 or severe COVID-19. (**B**) Overlapped or separated areas under the curve for the distributions in
673 (A). (**C**) Cumulative distributions of URT shedding for adults with nonsevere or severe COVID-
674 19 at various DFSO. (**D**) Estimated accuracy for using URT shedding of SARS-CoV-2 as a
675 prognostic indicator for COVID-19 severity. (**E**) Estimated distributions at 5, 6, 8 and 10 DFSO
676 of lower respiratory tract (LRT) shedding for adults with nonsevere or severe COVID-19. (**F**)
677 Overlapped or separated areas under the curve for the distributions in (E). (**G**) Cumulative
678 distributions of LRT shedding for adults with nonsevere or severe COVID-19 at various DFSO.
679 (**H**) Estimated accuracy for using LRT shedding of SARS-CoV-2 as a prognostic indicator for
680 COVID-19 severity. Arrows in (A) and (E) denote the 80th case percentiles, in terms of rVL, for
681 each group. For (C) and (G), the proportion of cases to the left of a given prognostic threshold
682 are predicted to have nonsevere COVID-19 while those to the right of it are predicted to have
683 severe disease. Sensitivity and specificity can then be estimated using the nonsevere and severe
684 distributions. The dotted lines in (D) and (H) denote 50% accuracy.

685 **FIGURE SUPPLEMENTS**



686

687 **Figure 1—Figure supplement 1.** Summary of rVLs in the systematic dataset. **(A)** URT rVLs for

688 adult COVID-19 cases (from -3 to 10 days from symptom onset [DFSO], *n* = 0, 3, 12, 71, 145,

689 159, 176, 152, 114, 123, 161, 125, 110, and 117 samples per DFSO). **(B)** LRT rVLs for adult

690 COVID-19 cases (from -3 to 10 DFSO, *n* = 0, 0, 1, 0, 0, 1, 8, 10, 18, 23, 31, 39, 40, and 40

691 samples per DFSO). **(C)** URT rVLs for pediatric COVID-19 cases (from -3 to 10 DFSO, *n* = 1,

692 1, 2, 8, 17, 20, 11, 14, 16, 25, 26, 20, 17, and 14 samples per DFSO). Data were collected within

693 the estimated infectious period of SARS-CoV-2 (-3 to 10 DFSO). The systematic search found

694 no quantitative specimen measurements from the LRT for pediatric COVID-19. Open circles

695 show rVL data. Filled circles and bars depict mean estimates and 95% CIs, respectively.



696

697 **Figure 2—Figure supplement 1. SARS-CoV-2 shedding in the URT for adult COVID-19.**

698 (**A** to **D**) Upper respiratory tract (URT) shedding for male and female adult (aged 18 y or older)

699 cases with nonsevere COVID-19 (A), for male and female adult cases with severe COVID-19

700 (B), for older (aged 60 y or older) and younger (aged 18-59 y) adults with nonsevere COVID-19

701 (C) and for older and younger adults with severe COVID-19 (D). Open circles represent rVL

702 data and were offset from their DFSO for visualization. Lines and bands show regressions and

703 their 95% CIs, respectively.



704

705 **Figure 2—Figure supplement 2. SARS-CoV-2 shedding in the URT for pediatric COVID-**

706 **19.** (**A**) Upper respiratory tract (URT) shedding for male and female pediatric (aged 0-17 y)

707 cases with nonsevere COVID-19. Open circles represent rVL data and were offset from their

708 DFSO for visualization. Lines and bands show regressions and their 95% CIs, respectively. (**B**)

709 Estimated distributions at 2, 6 and 10 days from symptom onset (DFSO) of URT shedding for

710 adult (aged 18 y or older) and pediatric cases with nonsevere COVID-19.



Figure 3—Figure supplement 1. SARS-CoV-2 shedding in the LRT for adult COVID-19. (**A** and **B**) Lower respiratory tract (LRT) shedding for older (aged 60 y or older) or younger (aged 18-59 y) adult cases with severe COVID-19 (A) and male adult (aged 18 y or older) cases severe COVID-19 (B). Open circles represent rVL data and were offset from their DFSO for visualization. Lines and bands show regressions and their 95% CIs, respectively.



Figure 4—Figure supplement 1. Few cases carry the majority of SARS-CoV-2 copies in the URT and LRT. (**A** to **D**) Cumulative distribution of upper respiratory tract (URT) SARS-CoV-2 copies harbored in adults with nonsevere or severe COVID-19 at 2 (A), 4 (B), 7 (C) and 10 (D) days from symptom onset (DFSO). (**E** to **H**) Cumulative distribution of lower respiratory tract (LRT) SARS-CoV-2 copies harbored in adults with nonsevere or severe COVID-19 at 5 (A), 6 (B), 8 (C) and 10 (D) DFSO. These curves were based on the fitted Weibull distributions in copies/ml and estimate the proportion of cases that carry the total amount of SARS-CoV-2 in the URT or LRT. The dotted lines denote when the upper case percentiles harbor 80% of copies.



Figure 4—Figure supplement 2. Estimated sensitivity and specificity of URT shedding as a prognostic indicator for SARS-CoV-2 infection. (**A** to **D**) Metrics for the accuracy of SARS-CoV-2 quantitation from the upper respiratory tract (URT) as a prognostic indicator for COVID-19 severity. Estimated true positive, true negative, false positive and false negative (top) or sensitivity and specificity (bottom) at 2 (A), 4 (B), 7 (C) and 10 (D) days from symptom onset (DFSO) across SARS-CoV-2 respiratory viral loads as the prognostic threshold. As depicted throughout this study, these plots show respiratory viral loads (rVLs, viral RNA concentration in the respiratory tract) rather than specimen concentrations (viral RNA concentration quantitated from a respiratory specimen).



Figure 4—Figure supplement 3. Estimated sensitivity and specificity of LRT shedding as a prognostic indicator for SARS-CoV-2 infection. (**A** to **D**) Metrics for the accuracy of SARS-CoV-2 quantitation from the lower respiratory tract (LRT) as a prognostic indicator for COVID-19 severity. Estimated true positive, true negative, false positive and false negative (top) or sensitivity and specificity (bottom) at 2 (A), 4 (B), 7 (C) and 10 (D) days from symptom onset (DFSO) across SARS-CoV-2 respiratory viral loads as the prognostic threshold. As depicted throughout this study, these plots show respiratory viral loads (rVLs, viral RNA concentration in the respiratory tract) rather than specimen concentrations (viral RNA concentration quantitated from a respiratory specimen).

746 **FIGURE DATA SOURCES**

747 **Figure 1—Source Data 1.** Search strategy used for MEDLINE.

Database: **Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily** 1946 to 20 Nov 2020	
#	**Searches**
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	exp Betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kf.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kf.
6	(pneumonia.tw,kf. Or exp pneumonia/) and (Wuhan or Hubei).tw,kf.
7	COVID-19.rx,px,ox. Or severe acute respiratory syndrome coronavirus 2.os.
8	exp Influenza A Virus, H1N1 Subtype/
9	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kf.
10	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kf.
12	Nasal cavity/vi
13	Sputum/vi
14	Nasopharynx/vi
15	Oropharynx/vi
16	*Saliva/vi
17	Pharynx/vi
18	(clinical adj2 (sample* or specimen*)).tw,kf.
19	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kf.
20	Influenza, Human/vi
21	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi
22	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
23	11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24	10 and 23
25	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kf.
26	(((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kf.

27	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kf.
28	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kf.
29	Viral load/
30	Viral shedding/
31	(“copy/m*” or “copies/m*” or “copy/test*” or “copies/test*”).tw,kf.
32	((test or diagnos*) adj2 sensitiv*).tw,kf.
33	25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34	24 and 33
35	animals/ not humans/
36	34 not 35

749 **Figure 1— Source Data 2.** Search strategy used for EMBASE.

Database: **Embase** 1974 to 20 Nov 2020	
#	**Searches**
1	coronavirus infection/ or severe acute respiratory syndrome/
2	COVID 19/
3	coronavirus disease 2019/
4	severe acute respiratory syndrome coronavirus 2/ or SARS coronavirus 2/
5	SARS coronavirus/ or betacoronavirus/
6	"influenza a virus (h1n1)"/
7	2009 h1n1 influenza/ or "influenza a (h1n1)"/
8	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or Sudden acute respiratory syndrome*).tw,kw.
9	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
10	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
11	(covid or SARS or H1N1 or coronavirus).ox.
12	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kw.
13	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14	nose smear/
15	smear/ or nose smear/ or sputum smear/
16	*sputum/
17	*nasopharynx/ or *pharynx/
18	throat culture/
19	saliva analysis/
20	*oropharynx/
21	exp nasopharyngeal aspiration/
22	real time polymerase chain reaction/ or real time reverse transcription polymerase chain reaction/ or reverse transcription polymerase chain reaction/
23	(clinical adj2 (sample* or specimen*)).tw,kw.
24	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kw.
25	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kw.
26	*2009 H1N1 influenza/di or coronavirus disease 2019/di or Coronavirus infection/di
27	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

28	13 and 27
29	virus load/
30	virus shedding/
31	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
32	(((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.
33	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.
34	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.
35	(“copy/m*” or “copies/m*” or “copy/test*” or “copies/test*”).tw,kw.
36	((test or diagnos*) adj2 sensitiv*).tw,kw.
37	29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38	28 and 37
39	exp animal/ not human/
40	38 not 39

750

751 **Figure 1— Source Data 3.** Search strategy used for Cochrane Central.

Database: **EBM Reviews – Cochrane Central Register of Controlled Trials** 20 Nov 2020	
#	**Searches**
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kw.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
6	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
7	exp Influenza A Virus, H1N1 Subtype/
8	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kw.
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kw.
11	Nasal cavity/
12	Sputum/
13	Nasopharynx/
14	Oropharynx/
15	*Saliva/
16	Pharynx/
17	(clinical adj2 (sample* or specimen*)).tw,kw.
18	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kw.
19	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi
20	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
21	10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22	9 and 21
23	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
24	(((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.
25	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.

26	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.
27	Viral load/
28	Viral shedding/
29	(“copy/m*” or “copies/m*” or “copy/test*” or “copies/test*”).tw,kw.
30	((test or diagnos*) adj2 sensitiv*).tw,kw.
31	23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32	22 and 31

752

753 **Figure 1— Source Data 4.** Search strategy used for Web of Science Core Collection.

Web of Science Core Collection Database: **Web of Science Core Collection** up to 20 Nov 2020	
#	**Searches**
#1	TOPIC: ((coronavirus* or "corona virus*" or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or "sars-cov*" or sarscov* or "Sars-coronavirus*" or "Severe Acute Respiratory Syndrome*" or "sudden acute respiratory syndrome*" or "2019-ncov*" or 2019nCov* or "2019-novel CoV" or corona or ((novel or new or nouveau) NEAR/2 (CoV or Pandemi*)) OR (pneumonia and (Wuhan or Hubei)) or "A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) NEAR/4 "2009") or "influenza A" or "swine flu")) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
#2	TOPIC: (((respiratory NEAR/3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) NEAR/3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) NEAR/2 aspirat*) or NPA or ETA or (deep NEAR/4 saliva) or POS or "swab sample*" or "flocked swab*" or (clinical NEAR/2 (sample* or specimen*)) or "RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction")) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
#3	TOPIC: (("vir* load*" or "vir* shed*" or "vir* burden" or "vir* titer*" or "vir* titre*" or (vir* NEAR/2 count*) or ((copies or copy) NEAR/2 (ml or mls or milli* or microl*)) or ((RNA* or vir*) NEAR/2 concentration*) or (calibration NEAR/1 curve*) or (standard NEAR/1 curve*) or "ct value*" or "cycle threshold" or ((copies or copy) NEAR/2 test*) or ((copy or copies) NEAR/2 number*) or "copy/m*" or "copies/m*" or "copy/test*" or "copies/test*" or ((test or diagnos*) NEAR/2 sensitiv*))) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
#4	#3 AND #2 AND #1 Refined by: [excluding] WEB OF SCIENCE CATEGORIES: (VETERINARY SCIENCES) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

754

755 **Figure 1—Source Data 5.** Search strategy used for medRxiv and bioRxiv.

medRxiv + bioRxiv (via Publish or Perish program) up to 20 Nov 2020
Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR "swine flu" OR COVID19 or SARS) AND ("copies/ml" OR "copy/ml" OR "viral load" OR "copies/test" OR "copy/test" OR "copies per ml" OR "copy per ml") **Publication name:** MedRxiv
Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR "swine flu" OR COVID19 or SARS) AND ("copies/ml" OR "copy/ml" OR "viral load" OR "copies/test" OR "copy/test" OR "copies per ml" OR "copy per ml") **Publication name:** BioRxiv

756

APPENDIX

Appendix Table 1. Characteristics of contributing studies.

Study	Country	Case types*	No. of adult cases (nonsevere; severe)	No. of pediatric cases (nonsevere; severe)	URT specimens (ascertained† for age; sex; disease severity)	LRT specimens (ascertained† for age; sex; disease severity)	Reported treatment (type)‡	Volume of VTM reported	Specimen type (adjusted rVL)§	Risk of bias‖
Bal et al. (2020)	France	H, N, A, S	39 (38; 1)	0	47 (47; 47; 47)	0	N/A	No	NPS (yes)	*****
Benotmane et al. (2020)	France	H, A, S	37 (19; 18)	0	47 (47; 47; 47)	0	Yes (azithromycin, other antibiotics, azole antifungals, lopinavir-ritonavir, hydroxychloroquine, tocilizumab, high-dose corticosteroid, mycophenolate mofetil withdrawal, mycophenolic acid withdrawal, calcineurin inhibitors withdrawal, mammalian target of rapamycin withdrawal, delayed belatacept administration)	No	NPS (yes)	******
Biguenet et al. (2020)	France	H, N, A, S	453 (406; 47)	0	453 (453; 453; 453)	0	Yes (antibiotics, oseltamivir, hydroxychloroquine, corticosteroids, lopinavir-ritonavir, remdesivir)	No	NPS (yes)	********
Fajnzylber et al. (2020)	USA	H, N, A, S	25 (9; 16)	0	31 (31; 31; 31)	11 (11; 11)	Yes (remdesivir)	Yes	(NPS (yes), OPS (yes), Spu (yes)	********
Han et al. (2020)	South Korea	H, P, S, As	0	12 (12; 0)	33 (33; 10; 33)	0	N/A	No	NPS (yes)	********
Hirotsu et al. (2020)	Japan	H, A, S	3 (3; 0)	0	9 (9; 9; 9)	0	N/A	No	NPS (yes)	****
Hurst et al. (2020)	USA	C, A, P, S, Ps	17 (17; 0)	76 (76; 0)	93 (93; 93; 93)	0	Yes (remdesivir)	No	NPS (yes)	********
Iwasaki et al. (2020)	Japan	H, A, S	5 (4; 1)	0	5 (5; 5; 5)	0	N/A	No	NPS (yes)	****
L'Huillier et al. (2020)	Switzerland	H, P, S	0	23 (23; 0)	23 (23; 0; 23)	0	N/A	No	NPS (yes)	********
Lavezzo et al. (2020)	Italy	H, C, A, P, S, Ps	40 (34; 6)	2 (2; 0)	6 (69; 69; 69)	0	N/A	Yes	NPS (yes), OPS (yes)	*******
Pan et al. (2020)	China	H, A, S, Ps	2 (2; 0)	0	13 (0; 0; 13)	12 (0; 12)	N/A	No	OPS (yes), Spu (no)	****
Peng et al. (2020)	China	H, A, S	6 (6; 0)	0	6 (6; 6; 6)	0	Yes (arbidol, lopinavir, ritonavir, interferon alfa-2b inhalation)	No	OPS (yes)	********
Shrestha et al. (2020)	USA	N, A, S	196 (196; 0)	1 (1; 0)	213 (213; 213; 213)	0	Yes (indicated no hydroxychloroquine or other	No	NPS (yes)	*******

							COVID-19–related treatments were used)			
Sun et al. (2020)	China	H, A, S	6 (3; 3)	0	6 (0; 0; 6)	0	N/A	No	NPS (yes), OPS (yes), Spu (no)	*****
To et al. (2020)	China	H, A, S	4 (2; 2)	0	2 (0; 0; 2)	2 (0; 2)	N/A	Yes	ETA (yes), POS (yes)	*********
van Kampen et al. (2021)	The Netherlands	H, A, S	171 (8; 163)	0	57 (57; 57; 57)	114 (114, 114)	Yes (lopinavir–ritonavir with or without ribavirin or interferon beta 1b)	Yes	NPS (yes), Spu (yes)	********
Vetter et al. (2020)	Switzerland	H, A, S	5 (4; 1)	0	63 (63; 63; 63)	0	Yes (paracetamol, alfuzosin, ibuprofen, enoxaparin, amoxicillin clarithromycin, piperacillin, tazobactam, lopinavir, ritonavir, folic acid)	Yes	NPS (yes), OPS (yes)	*********
Wölfel et al. (2020)	Germany	H, A, S, As	9 (9; 0)	0	71 (71; 0; 71)	70 (70; 0; 70)	N/A	Yes	NPS (yes), OPS (yes), Spu (no)	*******
Wyllie et al.	USA	H, A, P, S	31 (31; 0)	2 (2; 0)	33 (0; 0; 33)	0	N/A	Yes	NPS (yes)	*******
Xu et al. (2020)	China	H, P, S, Ps, As	0	9 (9; 0)	39 (39; 39; 39)	0	Yes (α-interferon oral spray, azithromycin)	No	NPS (yes)	********
Yazdanpanah et al. (2020)	France	H, A, Ps, S	125 (64; 61)	0	173 (173; 173; 173)	0	Yes (remdesivir, hydroxychloroquine, Lopinavir-ritonavir)	No	NPS (yes)	********
Yilmaz et al. (2020)	Sweden	H, A, S	52 (37; 12)	0	102 (102; 102; 102)	0	N/A	Yes	NPS (yes), OPS (yes)	*******
Yonker et al. (2020)	USA	H, A, P, S	3 (3; 0)	14 (13; 1)	14 (14; 0; 14)	0	N/A	No	NPS (yes)	******
Zhang et al. (2020)	China	H, A, S	4 (3; 1)	0	10 (10; 10; 10)	0	N/A	No	NPS (yes), OPS (yes)	********
Zheng et al. (2020)	China	H, A, S	17 (10; 7)	0	13 (13; 0; 13)	12 (12; 0; 12)	Yes (gammaglobulin, glucocorticoids, antibiotics, antiviral combination of interferon α inhalation, lopinavir-ritonavir combination, arbidol, favipiravir, and darunavir-cobicistat)	No	POS (yes), Spu (yes)	*******
Zou et al. (2020)	China	H, A, S, As	16 (13; 3)	0	88 (88; 88; 88)	0	N/A	No	NPS (yes), OPS (yes)	*******

H = hospitalized; N = non-admitted; C = community; A = adult (aged 18 y or older); P = pediatric (aged 0-17 y); S = symptomatic; Ps = presymptomatic; As = asymptomatic; rVL = respiratory viral load; endotracheal aspirate (ETA); nasopharyngeal swab (NPS); oropharyngeal swab (OPS); posterior oropharyngeal saliva (POS); and sputum (Spu).

* Hospitalized cases were those admitted to a hospital. Non-admitted cases were those tested in a hospital setting but not admitted. Community cases were those tested in a community setting.

† The number of specimens for which their cases were ascertained for age group (aged 0-17 y, 18-59 y or 60 y or older), sex (male or female) or disease severity (nonsevere or severe) via data reported in the study or via data request. All specimens were ascertained for the DFSO on which they were taken.

‡ Responses of “N/A” indicate that no details were reported on treatment for COVID-19 in the study.

§ Specimen measurements were converted to rVLs based on the reported, or assumed, dilution factor for specimens immersed in transport media.

[ll] The modified JBI critical appraisal checklist was used, with more stars indicating lower risk of bias. Studies were considered to have low risk of bias if they met the majority of the items (≥6/10 items) and met item 1. Results from each study are shown in **Appendix Table 2**.

769 **Appendix Table 2.** Assessment of risk of bias based on the modified JBI critical appraisal
770 checklist.

	Checklist items*									
Study	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**
Bal et al. (2020)										
Benotmane et al. (2020)										
Biguenet et al. (2020)										
Fajnzylber et al. (2020)										
Han et al. (2020)										
Hirotsu et al. (2020)										
Hurst et al. (2020)										
Iwasaki et al. (2020)										
L'Huillier et al. (2020)										
Lavezzo et al. (2020)										
Pan et al. (2020)										
Peng et al. (2020)										
Shrestha et al. (2020)										
Sun et al. (2020)										
To et al. (2020)										
van Kampen et al. (2020)										
Vetter et al. (2020)										
Wölfel et al. (2020)										
Wyllie et al. (2020)										
Xu et al. (2020)										
Yazdanpanah et al. (2020)										
Yilmaz et al. (2020)										
Yonker et al. (2020)										
Zhang et al. (2020)										
Zheng et al. (2020)										
Zou et al. (2020)										

771 *Descriptions of each item are included in the modified JBI critical appraisal checklist. Green, yellow and red represent yes, unclear and no,
772 respectively.

773 **Appendix Table 3.** Summary of respiratory shedding levels and dynamics for COVID-19
774 groups.

Group	*n**	rVL† (95% CI), *log_{10} copies/ml*		SARS-CoV-2 clearance rate	
		At 1 DFSO	At 4 DFSO	Estimate (95% CI), *log_{10} copies/ml day^{-1}*	*P* value ‡
URT, ≥18 y					
Nonsevere	1 092	7.45 (7.26-7.65)	6.62 (6.50-6.74)	-0.28 (-0.32 to -0.24)	<0.001
Severe	289	8.28 (7.71-8.84)	7.34 (7.01-7.68)	-0.31 (-0.40 to -0.22)	<0.001
Male (nonsevere)	382	7.66 (7.31-8.01)	-	-0.28 (-0.36 to -0.21)	<0.001
Female (nonsevere)	618	7.29 (7.05-7.54)	-	-0.26 (-0.32 to -0.21)	<0.001
Male (severe)	175	8.00 (7.23-8.78)	-	-0.27 (-0.39 to -0.15)	<0.001
Female (severe)	89	8.59 (7.65-9.54)	-	-0.38 (-0.54 to -0.22)	<0.001
Nonsevere (18-59 y)	857	7.53 (7.31-7.74)	-	-0.30 (-0.35 to -0.26)	<0.001
Nonsevere (≥60 y)	212	7.26 (6.77-7.74)	-	-0.22 (-0.31 to -0.12)	<0.001
Severe (18-59 y)	89	8.31 (7.28-9.33)	-	-0.37 (-0.54 to -0.21)	<0.001
Severe (≥60 y)	192	8.24 (7.54-8.93)	-	-0.28 (-0.39 to -0.16)	<0.001
LRT, ≥18 y §					
Nonsevere	80	-	6.82 (5.95-7.69)	-0.41 (-0.64 to -0.19)	<0.001
Severe	121	-	8.42 (7.67-9.17)	-0.14 (-0.32 to 0.030)	0.105 ‖
Male (severe)	94	-	7.84 (7.03-8.65)	0.001 (-0.16 to 0.19)	0.988 ‖
Severe (18-59 y)	55	-	8.64 (7.64-9.64)	-0.20 (-0.43 to 0.042)	0.105 ‖
Severe (≥60 y)	65	-	8.39 (7.26-9.52)	-0.13 (-0.39 to 0.13)	0.316 ‖
URT, 0-17 y					
Overall	180	7.32 (6.78-7.86)	-	-0.32 (-0.42 to -0.22)	<0.001
Male	64	6.41 (5.52-7.31)	-	-0.18 (-0.33 to -0.022)	0.026
Female	58	6.72 (5.59-7.85)	-	-0.30 (-0.49 to -0.10)	0.004

775 * *n* represents the number of rVL samples per group (from 1-10 DFSO for URT shedding or 4-10 DFSO for
776 LRT shedding).

777 † rVLs were based on the regression estimate at 1 DFSO for URT shedding or 4 DFSO for LRT shedding.
778 Estimates at 4 DFSO were included for the nonsevere and severe URT (≥18 y) groups, and they were
779 compared with their LRT counterparts.

780 ‡ *P* value for the clearance rate was based on the regression parameter (*t*-test).

781 § There was lower sample numbers in the nonsevere groups and female (LRT, severe, ≥18 y) group, and we
782 did not include these analyses.

783 ‖ Non-significance ($P > 0.05$).

784 **Appendix Table 4.** Summary of statistical comparisons on SARS-CoV-2 shedding, across the
785 respiratory tract, COVID-19 severity, sex and age groups

		P* value	
Group 1	**Group 2**	**Intercept†**	**Interaction‡**
URT, ≥18 y			
Nonsevere	Severe	0.005*	0.479
Female (nonsevere)	Male (nonsevere)	0.085	0.644
Female (severe)	Male (severe)	0.326	0.280
Nonsevere (18-59 y)	Nonsevere (≥60 y)	0.294	0.100
Severe (18-59 y)	Severe (≥60 y)	0.915	0.359
LRT, ≥18 y §			
Nonsevere	Severe	0.006*	0.053
Severe (18-59 y)	Severe (≥60 y)	0.745	0.716
URT vs. LRT, ≥18 y			
Nonsevere (URT, ≥18 y)	Nonsevere (LRT, ≥18 y)	0.651	0.231
Severe (URT, ≥18 y)	Severe (LRT, ≥18 y)	0.031*	0.151
URT, 0-17 y			
Nonsevere (0-17 y)	Nonsevere (≥18 y)	0.653	0.400
Nonsevere (0-17 y)	Severe (≥18 y)	0.017*	0.863
Female (nonsevere)	Male (nonsevere)	0.667	0.333

786 * $P < 0.05$.
787 † *P* value for the intercept in regression analysis compares the mean rVLs at 1 DFSO for the URT or, for any
788 analyses including the LRT, at 4 DFSO.
789 ‡ *P* value for interaction in regression analysis describes the difference in respiratory shedding dynamics along
790 the time course of disease.
791 § There were small sample sizes in the nonsevere group and female (LRT, severe, ≥18 y) group, and these
792 analyses were not included.

793

794 **Modified JBI critical appraisal checklist**
795
796 Reviewer_____Date_____
797
798 Author_____Year_____Record Number_____
799

	Yes	No	Unclear	Not applicable
1. Was the sample frame appropriate to address the target population?	□	□	□	□
2. Were the study subjects and the setting described in detail?	□	□	□	□
3. Did the study have consecutive inclusion of participants for case series and cohort studies? Did the study use probability-based sampling for cross-sectional studies?	□	□	□	□
4. Was the response rate adequate, and if not, was the low response rate managed appropriately?	□	□	□	□
5. Was the sample size adequate?	□	□	□	□
6. Were valid methods used for the identification of the condition?	□	□	□	□
7. Were standard, valid methods used for measurement of the exposure?	□	□	□	□
8. Was the exposure measured in an objective, reliable way for all participants	□	□	□	□
9. Was there clear reporting of clinical information of the participants?	□	□	□	□
10. Was statistical analysis appropriate?	□	□	□	□

800
801 Overall appraisal: Include □ Exclude □ Seek further info □
802
803 Comments (Including reason for exclusion)

804 _____

805 _____

806 _____

Tool Guidance

This modified checklist was based on a the JBI Critical Appraisal Checklists for case series, prevalence studies and analytical cross-sectional studies.

1. **Was the sample frame appropriate to address the target population?**

   This question relies upon knowledge of the broader characteristics of the population of interest and the geographical area.

   This study broadly investigates the respiratory viral load for the population of interest, which is the general population infected with SARS-CoV-2. The geographical area is not constrained. Sample frames restricted to particular subgroups within the general infected population were considered appropriate if they targeted one of the following groups analysed in our study: asymptomatic, presymptomatic, symptomatic, adult, pediatric, hospitalized, non-admitted, or community.

2. **Were the study subjects and the setting described in detail?**

   Certain diseases or conditions vary in prevalence across different geographic regions and populations (e.g. Women vs. Men, sociodemographic variables between countries). The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them

3. **Did the study have consecutive inclusion of participants for case series and cohort studies? Did the study use probability sampling for cross-sectional studies?**

   Inclusion of consecutive participants for case series and cohort studies yields results at lower risk of bias compared to other sampling methods for these study designs. Use of probability-based sampling methods for cross-sectional studies yields estimates at lower risk of bias compared to other sampling methods for this design. Studies that indicate a consecutive inclusion are more reliable than those that do not. For example, a case series that states ‘we included all patients (24) with osteosarcoma who presented to our clinic between March 2005 and June 2006’ is more reliable than a study that simply states ‘we report a case series of 24 people with osteosarcoma.’

4. **Was the response rate adequate, and if not, was the low response rate managed appropriately?**

   A large number of dropouts, refusals or “not founds” amongst selected subjects may diminish a study’s validity, as can a low response rates for survey studies. The authors should clearly discuss the response rate and any reasons for non-response and compare persons in the study to those not in the study, particularly with regards to their socio-demographic characteristics. If reasons for non-response appear to be unrelated to the outcome measured and the characteristics of non-responders are comparable to those who do respond in the study, the researchers may be able to justify a more modest response rate.

5. Was the sample size adequate?

The larger the sample, the narrower will be the confidence interval around the prevalence estimate, making the results more precise. An adequate sample size is important to ensure good precision of the final estimate. The sample size threshold was calculated as follows:

$$n^* = {z^2\sigma}/{d^2}$$

where n^* is the sample size threshold, z is the z-score for the level of confidence (95%), σ is the standard deviation (assumed to be 3 $\log_{10}$ copies/ml, a fourth of the full range of rVLs) and d is the marginal error (assumed to be 1 $\log_{10}$ copies/ml, based on the minimum detection limit for qRT-PCR across studies). This item was met if ≥75% of the included DFSO had ≥46 specimen measurements.

6. Were valid methods used for the identification of the condition?

Many health problems are not easily diagnosed or defined and some measures may not be capable of including or excluding appropriate levels or stages of the health problem. If the outcomes were assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If the outcomes were assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

7. Were standard, valid methods used for measurement of the exposure?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

In this study, standard methods to measure viral load in respiratory specimens are assays quantifying via one of the diagnostic sequences (*Ofr1b*, *N*, *RdRp* and *E* genes) for SARS-CoV-2.

8. Was the exposure measured in an objective, reliable way for all participants?

The study should clearly describe the procedural aspects of the measurement of exposure as well as factors that can contribute to heterogeneity in measurement.

In this study, objective, reliable interpretation of the exposure depends on the use of quantitative calibration; the specification of extraction; determination of the viral load as a standard metric (e.g., copies/ml or equivalent) or in a manner that can be converted to a standard metric; and, if present, specification of the amount of diluent (e.g., viral transport media) used.

9. Was there clear reporting of clinical information of the participants?

There should be clear reporting of clinical information of the participants such as the following information where relevant: disease status, comorbidities, stage of disease, previous interventions/treatment, results of diagnostic tests, etc.

In addition, there should be clear reporting of the number and types (asymptomatic, presymptomatic, symptomatic, adult, pediatric, hospitalized, non-admitted, community, etc.) of cases for measurements within the sampling periods of interest. For studies that include data outside of the infectious period, there should be clear reporting of clinical information for participants for the specimen measurements that were collected from within the infectious period.

10. Was statistical analysis appropriate?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section of studies should be detailed enough for reviewers to identify which analytical techniques were used and whether these were suitable.

Risk of bias for each study	
Low	The majority of critical appraisal criteria are met (≥6/10 items) and included item 1 (representative sample). The estimates are likely to be correct for the target population.
High	The majority of critical appraisal criteria are not met (<6/10 items) or did not include item 1 (representative sample). This may impact on the validity and reliability of the estimates. The estimates may not be correct for the target population.
Unclear	The majority of items are unclear. There was insufficient information to assess the risk of bias.